Key result
HbA1c >7.0% linked to ~25% higher stent failure risk versus HbA1c 6.1-7.0%.
Why the study?
The impact of glycemic control on the risk of stent failure in patients with type 2 diabetes is unknown.
Does poor glycemic control increase the risk of stent failure in patients with type 2 diabetes mellitus undergoing second-generation drug-eluting stent implantation?
Observational (n=52,457)
Yes
Does poor glycemic control increase the risk of stent failure in patients with type 2 diabetes mellitus undergoing second-generation drug-eluting stent implantation?
In patients with type 2 diabetes receiving second-generation drug-eluting stents, poor glycemic control is significantly associated with a higher risk of stent failure, driven primarily by in-stent restenosis.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We need to continue to investigate how we can improve treatment for patients with diabetes who undergo stent implantation. Our results indicate that there is a need to adapt treatment and follow-up for them.”
“Our results show that people with diabetes, especially type 1 diabetes, have a much higher risk of stent complications. Therefore, it is important to carefully consider how we treat these patients.”
No practice change for glycemic control in stented T2DM patients; leaves open causality and requires RCTs before adoption.
BACKGROUND: The impact of glycemic control in the risk of stent failure in subjects with type 2 diabetes (T2D) is currently unknown. OBJECTIVES: This study sought to study whether poor glycemic control is associated with a higher risk of stent failure in subjects with T2D. METHODS: This observational study included all patients in Sweden with T2D who underwent implantation of second-generation drug-eluting stents (DES) during 2010 to 2020. The exposure variable was the updated mean of glycated hemoglobin (HbA1c). Individuals were stratified by glycemic control, with HbA1c 6.1% to 7.0% (43-53 mmol/mol) as the reference group. The primary endpoint was the occurrence of stent failure (in-stent restenosis and stent thrombosis). The main result was analyzed in a complete cases model. Sensitivity analyses were performed for missing data and a model with death as a competing risk. RESULTS: The study population consisted of 52,457 individuals (70,453 DES). The number of complete cases was 24,411 (29,029 DES). The median follow-up was 6.4 years. The fully adjusted HR was 1.10 (95% CI: 0.80-1.52) for HbA1c of ≤5.5% (≤37 mmol/mol), 1.02 (95% CI: 0.85-1.23) for HbA1c of 5.6% to 6.0% (38-42 mmol/mol), 1.25 (95% CI: 1.11-1.41) for HbA1c of 7.1% to 8.0% (54-64 mmol/mol), 1.30 (95% CI: 1.13-1.51) for HbA1c of 8.1% to 9.0% (65-75 mmol/mol), 1.46 (95% CI: 1.21-1.76) for HbA1c of 9.1% to 10.0% (76-86 mmol/mol), and 1.33 (95% CI: 1.06-1.66) for HbA1c of ≥10.1% (≥87 mmol/mol). Sensitivity analyses did not change the main result. CONCLUSIONS: We found a significant association between poor glycemic control and a higher risk of stent failure driven by in-stent restenosis.
No takes yet. Share an insight, caveat, or question.
Santos‐Pardo et al. (2024) conducted an observational in Type 2 diabetes mellitus (n=52,457). Updated mean of glycated hemoglobin (HbA1c) vs. HbA1c 6.1% to 7.0% (43-53 mmol/mol) was evaluated on Occurrence of stent failure (in-stent restenosis and stent thrombosis) (HR 1.25, 95% CI 1.11-1.41). Poor glycemic control was associated with a higher risk of stent failure compared to HbA1c 6.1-7.0%, with hazard ratios ranging from 1.25 to 1.46.
Synapse has enriched 10 related papers. Consider them for comparative context: